Magnolia Advanced Materials Is Exhibiting at SAMPE 2025

ATLANTA--(BUSINESS WIRE)-- Magnolia Advanced Materials, Inc., a leading custom formulator of high-performance epoxy systems, will exhibit at SAMPE 2025 on May 20 and May 21, 2025, at the Indiana Convention Center in Indianapolis, IN. Attendees can visit Magnolia Advanced Materials and its representatives at Booth L8.

Magnolia President and CEO Wayne Tanner, along with Technical Director Greg Bunn, Technical Service Manager Gary Betzel and Order Fulfillment Manager Renata Negre, will be on hand to greet visitors and answer questions about the company’s industry best lead times and custom-formulated adhesives, sealants and functional coatings.

“We’re always delighted to make new connections and shake hands with familiar friends and customers at SAMPE,” said Tanner.

Hosted by the Society for the Advancement of Material and Process Engineering (SAMPE), SAMPE 2025 is North America's premier advanced materials and process engineering conference and exhibition trade show.

About Magnolia Advanced Materials

Magnolia Advanced Materials, Inc. is a privately held manufacturer of custom high-performance epoxy systems that offers short lead times and exceptional customer service. The company sells its portfolio of adhesives, coatings, encapsulating and potting compounds, syntactics, tooling resins and general purpose epoxy resins and curing agents to customers worldwide—across industries that include aerospace, defense, civil engineering, communication, electronics, electrical energy, marine, recreation and transportation. For more information, please visit us at MagnoliaAdvanced.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250415820430/en/

Media Contact
Tracey Slauer
[email protected]

Source: Magnolia Advanced Materials, Inc.

You May Also Be Interested In

• Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and
• Cryptocurrency News: $431M in Bets Wiped Out in a Day as Pepeto Buyers Chase Gains Like Ethereum’s First Holders
• Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule